$97.64
+0.74
(+0.76%)
As of Oct 5, 2026, 5:11 PM EDT
Price history
BioNTech (BNTX) is trading up at $97.64 (+0.76%), as of the latest quote. It operates in the Health Care sector.
IPO: October 10, 2019 · $15.00 offering · NASDAQ · View IPO details →
BioNTech revenue & net income history (FY2017–FY2025)
RevenueNet income
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | €61.6M | €127.6M | €108.6M | €482.3M | €19.0B | €17.3B | €3.82B | €2.75B | €2.87B |
| Growth (year over year) | — | +107.1% | −14.9% | +344.1% | +3834.6% | −8.8% | −77.9% | −28.0% | +4.3% |
| Gross profit | €52.3M | €113.9M | €91.2M | €423.0M | €16.1B | €14.3B | €3.22B | €2.21B | €2.23B |
| Gross margin | 84.9% | 89.3% | 84.0% | 87.7% | 84.7% | 82.7% | 84.3% | 80.3% | 77.6% |
| Operating income | −€61.3M | −€53.9M | −€181.5M | −€82.4M | €15.3B | €12.6B | €690.4M | −€1.31B | −€1.40B |
| Operating margin | −99.5% | −42.2% | −167.1% | −17.1% | 80.5% | 73.0% | 18.1% | −47.8% | −49.0% |
| Net income | −€85.7M | −€48.0M | −€179.1M | €15.2M | €10.3B | €9.43B | €930.3M | −€665.3M | −€1.14B |
| Net margin | −139.1% | −37.6% | −164.9% | 3.2% | 54.2% | 54.5% | 24.4% | −24.2% | −39.6% |
| EPS (diluted) | −€0.51 | −€0.25 | −€0.85 | €0.06 | €39.63 | €37.77 | €3.83 | −€2.77 | −€4.70 |
| Balance sheet | |||||||||
| Cash and equivalents | €172.1M | €411.5M | €519.1M | €1.21B | €1.69B | €13.9B | €11.7B | €9.76B | €7.68B |
| Total assets | — | €653.0M | €797.6M | €2.32B | €15.8B | €23.3B | €23.0B | €22.5B | €22.0B |
| Total liabilities | — | €386.0M | €304.2M | €946.8M | €3.94B | €3.22B | €2.76B | €3.12B | €2.76B |
| Shareholders' equity | −€48.2M | €266.2M | €493.5M | €1.37B | €11.9B | €20.1B | €20.2B | €19.4B | €19.2B |
| Cash flow | |||||||||
| Operating cash flow | −€52.6M | −€58.9M | −€198.5M | −€13.5M | €889.7M | €13.6B | €5.37B | €207.7M | €456.0M |
| Capital expenditure | €24.3M | €29.9M | €38.6M | €66.0M | €127.5M | €329.2M | €249.4M | €286.5M | €175.1M |
| Free cash flow | −€76.9M | −€88.8M | −€237.1M | −€79.5M | €762.2M | €13.2B | €5.12B | −€78.8M | €280.9M |
| Dividends paid | — | — | — | €0 | €0 | €484.3M | €0 | €0 | — |
From BioNTech's 20-F filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Euro (EUR), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
About BioNTech
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
- Headquarters
- Mainz, Germany From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with BNTX
- BMEA Biomea Fusion
- BMRN BioMarin Pharmaceutical
- BNR Burning Rock Biotech
- BNTC Benitec Biopharma Inc
- BOLD Boundless Bio
- BOLT Bolt Biotherapeutics
- BON Bon Natural Life
- BRKR Bruker